• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Application of a method of analysis using high performance liquid chromatography of isoniazid and acetylisoniazid to determine the phenotype of acetylation].

作者信息

Miscoria G, Leneveu A, Walle C, Roux A

机构信息

Laboratoire de Toxicologie et de Pharmacocinétique, Hôpital Ambroise-Paré, Boulogne.

出版信息

Ann Biol Clin (Paris). 1988;46(9):734-40.

PMID:3223632
Abstract

The described method is adapted from Moulin to measure plasma levels of isoniazid (INH) and acetylisoniazid (AINH) after extraction, HPLC separation and UV detection (254 nm). INH and AINH plasma levels of 109 patients aged between four months to 87 years were measured, allowing dosage individualization. The ratio of AINH to INH (Rm) three hours after administration was calculated. Rm allows determination of the patient acetylation phenotype: in fast acetylators with INH half-life shorter than 1.8 h, Rm is greater than 0.77 and in slow acetylators with INH half-life longer than 1.8 h, Rm is less than 0.48.

摘要

相似文献

1
[Application of a method of analysis using high performance liquid chromatography of isoniazid and acetylisoniazid to determine the phenotype of acetylation].
Ann Biol Clin (Paris). 1988;46(9):734-40.
2
Determination of the acetylator phenotype in Moroccan tuberculosis patients using isoniazid as metabolic probe.以异烟肼作为代谢探针测定摩洛哥结核病患者的乙酰化表型。
Int J Clin Pharmacol Ther. 2002 Dec;40(12):548-53. doi: 10.5414/cpp40548.
3
Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans.异烟肼在人体内形成的有毒肼类代谢产物的药代动力学。
J Pharmacol Exp Ther. 1985 Dec;235(3):566-70.
4
Isoniazid acetylation metabolic ratio during maturation in children.儿童发育过程中异烟肼乙酰化代谢率
Clin Pharmacol Ther. 1997 Oct;62(4):377-83. doi: 10.1016/S0009-9236(97)90115-6.
5
[Testing for heterogeneity in genetic polymorphism of N-acetylation using isoniazid by metameters--probit, logit, and arcsine transformation].[使用异烟肼通过元测量法(概率单位、对数单位和反正弦变换)检测N-乙酰化遗传多态性的异质性]
Kekkaku. 1993 Aug;68(8):511-6.
6
Isoniazid acetylation phenotyping in Saudi Arabs.沙特阿拉伯人的异烟肼乙酰化表型分析
J Clin Pharm Ther. 2004 Oct;29(5):443-7. doi: 10.1111/j.1365-2710.2004.00588.x.
7
[Type of isoniazid (INH) acetylation determined in tuberculosis patients treated at the Institute of Tuberculosis and Lung Diseases in Warsaw during the years 1990-1997].[1990年至1997年期间在华沙结核病与肺部疾病研究所接受治疗的结核病患者中异烟肼(INH)乙酰化类型的测定]
Pneumonol Alergol Pol. 2002;70(3-4):180-92.
8
The type of isoniazid acetylation in tuberculosis patients treated at National Tuberculosis and Lung Diseases Research Institute.在国家结核病和肺部疾病研究所接受治疗的结核病患者中异烟肼乙酰化的类型
Acta Pol Pharm. 2002 Nov-Dec;59(6):443-7.
9
A simple method for determining acetylator phenotype using isoniazid.一种使用异烟肼测定乙酰化酶表型的简单方法。
Br J Clin Pharmacol. 1986 Sep;22(3):343-5. doi: 10.1111/j.1365-2125.1986.tb02897.x.
10
[The pharmacokinetics of isoniazid in children (author's transl)].
Rev Fr Mal Respir. 1981;9(5):365-74.

引用本文的文献

1
Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy - case report and literature review.慢性透析、N-乙酰转移酶2基因多态性与异烟肼所致脑病的风险——病例报告及文献综述
BMC Nephrol. 2017 Sep 4;18(1):282. doi: 10.1186/s12882-017-0703-6.
2
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.接受基于奈韦拉平或依非韦伦的抗逆转录病毒治疗的结核合并艾滋病病毒感染患者中利福平与异烟肼的药代动力学
Antimicrob Agents Chemother. 2014 Jun;58(6):3182-90. doi: 10.1128/AAC.02379-13. Epub 2014 Mar 24.
3
Is there any difference between acetylator phenotypes in tuberculosis patients and healthy subjects?
肺结核患者和健康受试者的乙酰化表型有差异吗?
Eur J Clin Pharmacol. 2010 Mar;66(3):261-7. doi: 10.1007/s00228-009-0745-1.